The university’s asymptomatic testing program is conducted in collaboration with Shield T3.
The U.S. Food and Drug Administration (FDA) has approved the Shield T3 under an Emergency Use Authorization (EUA). The asymptomatic testing program uses a saliva-based test and the commercially available TaqPath RT-PCR COVID-19 kit, developed and marketed by Thermo Fisher Scientific. A copy of Shield’s laboratory developed test validation report is available here.
In connection with the asymptomatic testing program, the university has designated an ordering provider within the university’s Public Health Central Command Center who interfaces with Shield T3.
Testing samples are disposed of as medical waste and are not saved/stored by either Vanderbilt or Shield T3. Information about the university’s approach to protection of privacy in connection with its COVID-19 protocols, including testing through Shield T3, is available here.
In addition, the university’s contractual agreement with Shield T3 requires Shield T3 to comply with applicable federal and state privacy and security laws and regulations, including the Health Insurance Portability and Accountability Act of 1996 and the Family Educational Rights and Privacy Act.